Finally, using biopsy samples, this study detected treatment-related alterations in the expression of six genes, including α-methylacyl-coA racemase (AMACR), androgen receptor-regulated long non-coding RNA (ARLNC1), C1orf64, SLIT1, RP11-672G23-1, and RP1-274L7.1, which may play a role in the development of prostate cancer and are important targets for future studies. This evidence concerns the gene AR and prostate carcinoma.